SGLT-2 inhibitors, as multifunctional drugs, have demonstrated solid renal and cardiovascular protective effects in the treatment of non-diabetic CKD, significantly expanding their clinical application and value [105]. The gene discussed is SLC5A2; the disease is chronic kidney disease.